Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial

J Antimicrob Chemother. 2012 Jul;67(7):1804-6. doi: 10.1093/jac/dks102. Epub 2012 Mar 27.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / administration & dosage*
  • Antiretroviral Therapy, Highly Active / methods*
  • Biomarkers / blood
  • C-Reactive Protein / analysis*
  • Darunavir
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • HIV Infections / pathology
  • Hepatitis C / complications
  • Hepatitis C / pathology
  • Humans
  • Interleukin-6 / blood*
  • Male
  • Ritonavir / administration & dosage*
  • Sulfonamides / administration & dosage*
  • Time Factors

Substances

  • Anti-HIV Agents
  • Biomarkers
  • Interleukin-6
  • Sulfonamides
  • C-Reactive Protein
  • Ritonavir
  • Darunavir